<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04520048</url>
  </required_header>
  <id_info>
    <org_study_id>APHP200237</org_study_id>
    <secondary_id>2019-A03207-50</secondary_id>
    <nct_id>NCT04520048</nct_id>
  </id_info>
  <brief_title>Vascular Biomarkers Predictive of the Progression From Gestational Hypertension to Preeclampsia in Pregnant Women</brief_title>
  <acronym>BIOVASC-PreHTA</acronym>
  <official_title>Exploratory Study. Endothelium-dependent Vasodilatation and Other Biomarkers: Predictive Indicators of the Progression From Gestational Hypertension to Preeclampsia?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypertension during pregnancy remains a leading cause of maternal and foetal morbidity and&#xD;
      mortality. The frequency (5 to 10% of pregnancies) and potential severity of these diseases,&#xD;
      both for the mother and the child, are reasons for standardizing and optimizing medical&#xD;
      practices.&#xD;
&#xD;
      The cause of hypertension during pregnancy and in particular the pathophysiology of&#xD;
      preeclampsia remains poorly understood. Guidelines distinguish these two entities by the&#xD;
      existence of proteinuria from and after the 20th week of amenorrhea and by maternal-foetal&#xD;
      complications, more serious in pre-eclampsia than in gestational hypertension.&#xD;
&#xD;
      During gestational hypertension and preeclampsia acute placental vasculature and blood flow&#xD;
      abnormalities were observed, maybe due to generalized vascular endothelial activation and&#xD;
      vasospasm resulting in systemic hypertension and organ hypoperfusion. Endothelial dysfunction&#xD;
      and abnormal expression of several specific blood biomarkers are now well accepted as&#xD;
      characteristics of preeclampsia.&#xD;
&#xD;
      However, the progression of gestational hypertension to preeclampsia is difficult to predict;&#xD;
      between 15 and 40 % of gestational hypertension cases progress to preeclampsia, suggesting&#xD;
      that it is the same worsening disease.&#xD;
&#xD;
      Endothelial dysfunction could be at the origin of gestational hypertension, and subsequent&#xD;
      development of preeclampsia through an imbalance between pro- and anti-angiogenic factors.&#xD;
&#xD;
      The main objective of this research is to assess whether the alteration of&#xD;
      endothelium-dependent vasodilatation in pregnant women with stable hypertension is correlated&#xD;
      with the occurrence of preeclampsia later during pregnancy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypertension in pregnancy is defined by PAS ≥140 mmHg and/or PAD ≥ 90 mmHg, mild to moderate&#xD;
      hypertension by PAS = 140-159 mmHg and/or PAD = 90-109 mmHg and severe hypertension by PAS ≥&#xD;
      160 mmHg and/or PAD ≥ 110 mmHg.&#xD;
&#xD;
      During gestational hypertension (GE) there is no pathologic elevation of proteinuria (after&#xD;
      20 weeks of amenorrhea). Preeclampsia (PE) is defined as high blood pressure (controlled or&#xD;
      uncontrolled) associated with proteinuria discovered after the 20th week of amenorrhea.&#xD;
&#xD;
      The cause of hypertension during pregnancy and in particular of preeclampsia remains poorly&#xD;
      understood. Endothelial dysfunction and abnormal blood levels of several biomarkers are&#xD;
      associated with PE, such as: soluble Fms-like- tyrosine kinase 1 (sFlt-1), Placental Growth&#xD;
      Factor (PIGF) and Vascular Endothelial Growth Factor (VEGF). VEGF is of particular importance&#xD;
      due to its direct vasodilating effect at systemic level through its interaction with nitric&#xD;
      oxide (NO). There is a bi-directional regulation between VEGF and NO, which has direct&#xD;
      implications for endothelium, capillary permeability and angiogenesis. sFlt-1 (circulating&#xD;
      form of VEGF receptor) has the property of neutraliting the growth factors VEGF and PIGF.&#xD;
      Inhibition of VEGF has a known biological effect on endothelial function in adults and is&#xD;
      believed to be a key factor in explaining elevated blood pressure. This has been demonstrated&#xD;
      in patients undergoing anti-angiogenic therapy in combination with chemotherapy. Other&#xD;
      biomarkers of preeclampsia are less known and could be involved in pathophysiological&#xD;
      mechanisms; mainly hypervolemia, renal dysfunction and activation of inflammation. The&#xD;
      progression of gestational hypertension to preeclampsia is difficult to predict; between 15&#xD;
      and 40 % of gestational hypertension cases progress to preeclampsia, suggesting that it is a&#xD;
      single worsening disease. Preeclampsia is known to be one of the few diseases in which acute&#xD;
      placental abnormalities manifest at the mother's vascular and renal system levels. These&#xD;
      abnormalities are attributable to generalized vascular endothelial activation and vasospasm,&#xD;
      resulting in hypertension and hypoperfusion of organs.&#xD;
&#xD;
      Endothelial dysfunction could be at the origin of gestational hypertension, and subsequently&#xD;
      itself contribute to the subsequent development of preeclampsia through an imbalance between&#xD;
      pro- and anti-angiogenic factors likely in relation with increased oxidative stress.&#xD;
&#xD;
      It is now accepted that angiogenic biomarkers (such as soluble fms-like tyrosine kinase 1,&#xD;
      Placenta growth factor and soluble endoglin) contribute to endothelial dysfunction through&#xD;
      VEGF antagonizing among others. The dosage of these angiogenic biomarkers in the maternal&#xD;
      bloodstream is highly predictive and significantly abnormal from the 23th week of amenorrhea&#xD;
      on average, and with a maximum peak between the 32th and 36th week of amenorrhea.&#xD;
&#xD;
      Endothelial dysfunction contributes to cardiovascular risk and can be measured by&#xD;
      Laser-Doppler technique coupled with transdermal administration of acetylcholine by&#xD;
      iontophoresis. This non-invasive technique has been validated and has already been used in&#xD;
      models of hypertension, including preeclamptic women.&#xD;
&#xD;
      The main objective is to assess whether the alteration of endothelium-dependent&#xD;
      vasodilatation in women with gestational hypertension is correlated with the occurrence of&#xD;
      preeclampsia later during pregnancy. Endothelium-dependent vasodilation can be achieved by a&#xD;
      validated method using Doppler-Laser skin blood flow measurement coupled with transdermal&#xD;
      iontophoresis of acetylcholine.&#xD;
&#xD;
      The investigators further explore a possible correlation of endothelium dysfunction with&#xD;
      other biomarkers of pre-eclampsia endothelial dysfunction and vascular involvement in&#xD;
      pregnancy hypertension.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">February 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Endothelium-dependent vasodilatation between 26 weeks and 34 weeks of pregnancy</measure>
    <time_frame>change between the 26th ± 2 week of amenorrhea and 34th ± 2 week of amenorrhea</time_frame>
    <description>Endothelium-dependent vasodilatation induced by local transdermal administration of acetylcholine measured by Doppler laser debimetry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in circulating levels of soluble Fms-like tyrosine kinase (sFlt-1) between 26 weeks and 34 weeks of pregnancy</measure>
    <time_frame>change between the 26th ± 2 week and 34th ± 2 week of amenorrhea</time_frame>
    <description>Determining of circulating levels of sFlt-1 in the serum of patients using un immunoassay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in circulating Placental Growth factor (PIGF) between 26 weeks and 34 weeks of pregnancy</measure>
    <time_frame>change between the 26th ± 2 week and 34th ± 2 week of amenorrhea</time_frame>
    <description>Determining of circulating levels of PlGF in the serum of patients using un immunoassay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in circulating levels of vascular endothelial growth factors (VEGF) between 26 weeks and 34 weeks of pregnancy</measure>
    <time_frame>change between the 26th ± 2 week and 34th ± 2 week of amenorrhea</time_frame>
    <description>Determining of circulating levels of VEGF in the serum of patients using un immunoassay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in circulating levels of soluble endogline (sEng) between 26 weeks and 34 weeks of pregnancy</measure>
    <time_frame>change between the 26th ± 2 week and 34th ± 2 week of amenorrhea</time_frame>
    <description>Determining of circulating levels of sEng-1 in the serum of patients using un immunoassay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in anti-angiotensin II receptor (AT1) between 26 weeks and 34 weeks of pregnancy</measure>
    <time_frame>change between the 26th ± 2 week and 34th ± 2 week of amenorrhea</time_frame>
    <description>Measurement of the anti-angiotensin II receptor (AT1) levels in the serum of patients using un immunoassay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in circulating Copetid between 26 weeks and 34 weeks of pregnancy</measure>
    <time_frame>change between the 26th ± 2 week and 34th ± 2 week of amenorrhea</time_frame>
    <description>Measurement of circulating Copetid levels in the serum of patients using un immunoassay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in circulating levels of Interleukin IL-17 between 26 weeks and 34 weeks of pregnancy</measure>
    <time_frame>change between the 26th ± 2 week and 34th ± 2 week of amenorrhea</time_frame>
    <description>Determining of circulating levels of Interleukin IL-17 in the serum of patients using un immunoassay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in urinary levels of Neutrophil Gelatinase-Associated Lipocalin (NGAL) between 26 weeks and 34 weeks of pregnancy</measure>
    <time_frame>change between the 26th ± 2 week and 34th ± 2 week of amenorrhea</time_frame>
    <description>Determining of urinary levels of NGAL using un immunoassay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in urinary Endothelial Microparticle Levels between 26 weeks and 34 weeks of pregnancy</measure>
    <time_frame>change between the 26th ± 2 week and 34th ± 2 week of amenorrhea</time_frame>
    <description>Determining of urinary levels of microparticules using flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in central aortic blood pressure between 26 weeks and 34 weeks of pregnancy</measure>
    <time_frame>change between the 26th ± 2 week and 34th ± 2 week of amenorrhea</time_frame>
    <description>Measurement of the aortic central arterial pressure (systolic and diastolic arterial pressure) by applanation tonometry, and the index of aortic increase by applanation tonometry, using the SphygmoCor® system (PWV Medical)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in carotid-femoral pulse wave velocity between 26 weeks and 34 weeks of pregnancy</measure>
    <time_frame>change between the 26th ± 2 week and 34th ± 2 week of amenorrhea</time_frame>
    <description>Measurement of the carotid-femoral pulse wave velocity using the SphygmoCor® system (PWV Medical)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">154</enrollment>
  <condition>Gestational Hypertension</condition>
  <condition>Pre-eclampsia</condition>
  <arm_group>
    <arm_group_label>Women with gestational hypertension and/or preeclampsia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pregnant patients from the 20th week of amenorrhea with the initial diagnosis of gestational hypertension and/or preeclampsia. Patients in a stable state undergoing follow-up consultation (day hospital and week hospitalisation)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laser Doppler coupled with acetylcholine iontophoresis</intervention_name>
    <description>Endothelium-dependent vasodilation measured by Laser-Doppler flowmetry coupled with transdermal administration of acetylcholine by iontophoresis</description>
    <arm_group_label>Women with gestational hypertension and/or preeclampsia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Aortic central pressure and the carotid-femoral pulse wave velocity</intervention_name>
    <description>Measurement of the aortic central arterial pressure (systolic and diastolic arterial pressure) by applanation tonometry, and the index of aortic increase by applanation tonometry, the carotid-femoral pulse wave velocity using the SphygmoCor® system (PWV Medical)</description>
    <arm_group_label>Women with gestational hypertension and/or preeclampsia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vascular biomarker assay</intervention_name>
    <description>Plasma biomarker levels determination using an immunoassay, including circulating sFlt-1, circulating PIGF, sFlt-1 / PIGF ratio, circulating VEGF, circulating soluble endoglin (sEng), anti-angiotensin II receptor (AT1), circulating copeptin, circulating interleukin 17 (IL-17). Urinary Neutrophil Gelatinase-Associated Lipocalin (NGAL) quantification as well as the urinary endothelial microparticules measurements using flow cytometry</description>
    <arm_group_label>Women with gestational hypertension and/or preeclampsia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with gestational hypertension and/or preeclampsia from the 20th amenorrhea&#xD;
             week until the 26th ± 2 amenorrhea week.&#xD;
&#xD;
          -  Age between 18 and 40 years old.&#xD;
&#xD;
          -  Having given written consent&#xD;
&#xD;
          -  Patients affiliated to a social security scheme&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of pathologies interfering in a major way with vascular parameters: diabetes&#xD;
             known before pregnancy (treated or not), hypertension known before pregnancy (treated&#xD;
             or not), hypercholesterolemia known (or LDL&gt;130 mg/dl), connectivitis, proven&#xD;
             cardiovascular disease (ischemic heart disease, stroke, arteriopathy of the lower&#xD;
             limbs, heart failure), pre-existing known renal failure (MDRD &lt;60 ml/min) and/or&#xD;
             pre-existing proteinuria ≥ 300 mg/24h).&#xD;
&#xD;
          -  Cardiac arrhythmia.&#xD;
&#xD;
          -  Hepatitis C, HIV infection (assay performed within 6 months prior to diagnosis of pre-&#xD;
             eclampsia)&#xD;
&#xD;
          -  Recent history of venous (pulmonary embolism, phlebitis) or arterial (myocardial&#xD;
             infarction, unstable angina, stroke, transient ischemic attack), thrombotic event ≤ 3&#xD;
             months.&#xD;
&#xD;
          -  Patient already engaged in a therapeutic protocol&#xD;
&#xD;
          -  Patients receiving State Medical Assistance&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Pregnant women</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marilucy LOPEZ-SUBLET, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AP-HP Avicenne Hospital, Department of Internal Medicine, ESH Hypertension European Excellence Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marilucy LOPEZ-SUBLET, MD</last_name>
    <phone>+33 (0)148955390</phone>
    <email>marilucy.lopez-sublet@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lionel CARBILLON, MD PhD</last_name>
    <phone>+33 (0)148026030</phone>
    <email>lionel.carbillon@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AP-HP Avicenne Hospital, Department of internal medicine</name>
      <address>
        <city>Bobigny</city>
        <state>Seine Saint Denis</state>
        <zip>93000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP Jean Verdier Hospital, Gynecology and obstetrics Department</name>
      <address>
        <city>Bondy</city>
        <state>Seine Saint Denis</state>
        <zip>93140</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Lionel CARBILLON, MD PhD</last_name>
      <phone>+33 (0)148026030</phone>
      <email>lionel.carbillon@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Lionel CARBILLON, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amélie BEBARA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol. 2000 Jul;183(1):S1-S22.</citation>
    <PMID>10920346</PMID>
  </reference>
  <reference>
    <citation>Wu P, Haththotuwa R, Kwok CS, Babu A, Kotronias RA, Rushton C, Zaman A, Fryer AA, Kadam U, Chew-Graham CA, Mamas MA. Preeclampsia and Future Cardiovascular Health: A Systematic Review and Meta-Analysis. Circ Cardiovasc Qual Outcomes. 2017 Feb;10(2). pii: e003497. doi: 10.1161/CIRCOUTCOMES.116.003497. Epub 2017 Feb 22. Review.</citation>
    <PMID>28228456</PMID>
  </reference>
  <reference>
    <citation>Myatt L, Roberts JM. Preeclampsia: Syndrome or Disease? Curr Hypertens Rep. 2015 Nov;17(11):83. doi: 10.1007/s11906-015-0595-4. Review.</citation>
    <PMID>26362531</PMID>
  </reference>
  <reference>
    <citation>Hod T, Cerdeira AS, Karumanchi SA. Molecular Mechanisms of Preeclampsia. Cold Spring Harb Perspect Med. 2015 Aug 20;5(10). pii: a023473. doi: 10.1101/cshperspect.a023473. Review.</citation>
    <PMID>26292986</PMID>
  </reference>
  <reference>
    <citation>Cain MA, Salemi JL, Tanner JP, Kirby RS, Salihu HM, Louis JM. Pregnancy as a window to future health: maternal placental syndromes and short-term cardiovascular outcomes. Am J Obstet Gynecol. 2016 Oct;215(4):484.e1-484.e14. doi: 10.1016/j.ajog.2016.05.047. Epub 2016 Jun 2.</citation>
    <PMID>27263996</PMID>
  </reference>
  <reference>
    <citation>Buchbinder A, Sibai BM, Caritis S, Macpherson C, Hauth J, Lindheimer MD, Klebanoff M, Vandorsten P, Landon M, Paul R, Miodovnik M, Meis P, Thurnau G; National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. Adverse perinatal outcomes are significantly higher in severe gestational hypertension than in mild preeclampsia. Am J Obstet Gynecol. 2002 Jan;186(1):66-71.</citation>
    <PMID>11810087</PMID>
  </reference>
  <reference>
    <citation>Antonios TF, Nama V, Wang D, Manyonda IT. Microvascular remodelling in preeclampsia: quantifying capillary rarefaction accurately and independently predicts preeclampsia. Am J Hypertens. 2013 Sep;26(9):1162-9. doi: 10.1093/ajh/hpt087. Epub 2013 Jun 11.</citation>
    <PMID>23757401</PMID>
  </reference>
  <reference>
    <citation>Debbabi H, Bonnin P, Ducluzeau PH, Lefthériotis G, Levy BI. Noninvasive assessment of endothelial function in the skin microcirculation. Am J Hypertens. 2010 May;23(5):541-6. doi: 10.1038/ajh.2010.10. Epub 2010 Feb 18.</citation>
    <PMID>20168305</PMID>
  </reference>
  <reference>
    <citation>Debbabi H, Bonnin P, Levy BI. Effects of blood pressure control with perindopril/indapamide on the microcirculation in hypertensive patients. Am J Hypertens. 2010 Oct;23(10):1136-43. doi: 10.1038/ajh.2010.115. Epub 2010 May 27.</citation>
    <PMID>20508624</PMID>
  </reference>
  <reference>
    <citation>Davis KR, Ponnampalam J, Hayman R, Baker PN, Arulkumaran S, Donnelly R. Microvascular vasodilator response to acetylcholine is increased in women with pre-eclampsia. BJOG. 2001 Jun;108(6):610-4.</citation>
    <PMID>11426896</PMID>
  </reference>
  <reference>
    <citation>Ramsay JE, Stewart F, Greer IA, Sattar N. Microvascular dysfunction: a link between pre-eclampsia and maternal coronary heart disease. BJOG. 2003 Nov;110(11):1029-31.</citation>
    <PMID>14592589</PMID>
  </reference>
  <reference>
    <citation>Agatisa PK, Ness RB, Roberts JM, Costantino JP, Kuller LH, McLaughlin MK. Impairment of endothelial function in women with a history of preeclampsia: an indicator of cardiovascular risk. Am J Physiol Heart Circ Physiol. 2004 Apr;286(4):H1389-93.</citation>
    <PMID>15020302</PMID>
  </reference>
  <reference>
    <citation>Khan F, Belch JJ, MacLeod M, Mires G. Changes in endothelial function precede the clinical disease in women in whom preeclampsia develops. Hypertension. 2005 Nov;46(5):1123-8. Epub 2005 Oct 17.</citation>
    <PMID>16230524</PMID>
  </reference>
  <reference>
    <citation>Hauth JC, Ewell MG, Levine RJ, Esterlitz JR, Sibai B, Curet LB, Catalano PM, Morris CD. Pregnancy outcomes in healthy nulliparas who developed hypertension. Calcium for Preeclampsia Prevention Study Group. Obstet Gynecol. 2000 Jan;95(1):24-8.</citation>
    <PMID>10636496</PMID>
  </reference>
  <reference>
    <citation>Hnat MD, Sibai BM, Caritis S, Hauth J, Lindheimer MD, MacPherson C, VanDorsten JP, Landon M, Miodovnik M, Paul R, Meis P, Thurnau G, Dombrowski M; National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine-Units. Perinatal outcome in women with recurrent preeclampsia compared with women who develop preeclampsia as nulliparas. Am J Obstet Gynecol. 2002 Mar;186(3):422-6. Erratum in: Am J Obstet Gynecol. 2003 Jul;189(1):244.</citation>
    <PMID>11904601</PMID>
  </reference>
  <reference>
    <citation>Chambers JC, Fusi L, Malik IS, Haskard DO, De Swiet M, Kooner JS. Association of maternal endothelial dysfunction with preeclampsia. JAMA. 2001 Mar 28;285(12):1607-12.</citation>
    <PMID>11268269</PMID>
  </reference>
  <reference>
    <citation>Powe CE, Levine RJ, Karumanchi SA. Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation. 2011 Jun 21;123(24):2856-69. doi: 10.1161/CIRCULATIONAHA.109.853127. Review.</citation>
    <PMID>21690502</PMID>
  </reference>
  <reference>
    <citation>Hirashima C, Ohkuchi A, Takahashi K, Suzuki H, Yoshida M, Ohmaru T, Eguchi K, Ariga H, Matsubara S, Suzuki M. Gestational hypertension as a subclinical preeclampsia in view of serum levels of angiogenesis-related factors. Hypertens Res. 2011 Feb;34(2):212-7. doi: 10.1038/hr.2010.212. Epub 2010 Nov 4.</citation>
    <PMID>21048778</PMID>
  </reference>
  <reference>
    <citation>Allen RE, Rogozinska E, Cleverly K, Aquilina J, Thangaratinam S. Abnormal blood biomarkers in early pregnancy are associated with preeclampsia: a meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2014 Nov;182:194-201. doi: 10.1016/j.ejogrb.2014.09.027. Epub 2014 Sep 22. Review.</citation>
    <PMID>25305662</PMID>
  </reference>
  <reference>
    <citation>Lam C, Lim KH, Karumanchi SA. Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension. 2005 Nov;46(5):1077-85. Epub 2005 Oct 17. Review.</citation>
    <PMID>16230516</PMID>
  </reference>
  <reference>
    <citation>SFHTA, M.-V.C.e.a., HTA et Grossesse. Consensus d'Experts de la Société Françaises d'Hypertension Artérielle. Consensus d'Experts avec le partenariat du Collège National des Gynécologues et Obstétriciens Français. 2015, Decembre: p. 1-5.</citation>
  </reference>
  <reference>
    <citation>Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004 Feb 12;350(7):672-83. Epub 2004 Feb 5.</citation>
    <PMID>14764923</PMID>
  </reference>
  <reference>
    <citation>Noori M, Donald AE, Angelakopoulou A, Hingorani AD, Williams DJ. Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension. Circulation. 2010 Aug 3;122(5):478-87. doi: 10.1161/CIRCULATIONAHA.109.895458. Epub 2010 Jul 19. Erratum in: Circulation. 2011 Sep 13;124(11):e302.</citation>
    <PMID>20644016</PMID>
  </reference>
  <reference>
    <citation>Kleinrouweler CE, Wiegerinck MM, Ris-Stalpers C, Bossuyt PM, van der Post JA, von Dadelszen P, Mol BW, Pajkrt E; EBM CONNECT Collaboration. Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: a systematic review and meta-analysis. BJOG. 2012 Jun;119(7):778-87. doi: 10.1111/j.1471-0528.2012.03311.x. Epub 2012 Mar 20. Review.</citation>
    <PMID>22433027</PMID>
  </reference>
  <reference>
    <citation>Karumanchi SA. Angiogenic Factors in Preeclampsia: From Diagnosis to Therapy. Hypertension. 2016 Jun;67(6):1072-9. doi: 10.1161/HYPERTENSIONAHA.116.06421. Epub 2016 Apr 11. Review.</citation>
    <PMID>27067718</PMID>
  </reference>
  <reference>
    <citation>Verlohren S, Perschel FH, Thilaganathan B, Dröge LA, Henrich W, Busjahn A, Khalil A. Angiogenic Markers and Cardiovascular Indices in the Prediction of Hypertensive Disorders of Pregnancy. Hypertension. 2017 Jun;69(6):1192-1197. doi: 10.1161/HYPERTENSIONAHA.117.09256. Epub 2017 May 1.</citation>
    <PMID>28461601</PMID>
  </reference>
  <reference>
    <citation>Bouloumié A, Schini-Kerth VB, Busse R. Vascular endothelial growth factor up-regulates nitric oxide synthase expression in endothelial cells. Cardiovasc Res. 1999 Mar;41(3):773-80.</citation>
    <PMID>10435050</PMID>
  </reference>
  <reference>
    <citation>Dulak J, Józkowicz A, Dembinska-Kiec A, Guevara I, Zdzienicka A, Zmudzinska-Grochot D, Florek I, Wójtowicz A, Szuba A, Cooke JP. Nitric oxide induces the synthesis of vascular endothelial growth factor by rat vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2000 Mar;20(3):659-66.</citation>
    <PMID>10712388</PMID>
  </reference>
  <reference>
    <citation>Motta-Mejia C, Kandzija N, Zhang W, Mhlomi V, Cerdeira AS, Burdujan A, Tannetta D, Dragovic R, Sargent IL, Redman CW, Kishore U, Vatish M. Placental Vesicles Carry Active Endothelial Nitric Oxide Synthase and Their Activity is Reduced in Preeclampsia. Hypertension. 2017 Aug;70(2):372-381. doi: 10.1161/HYPERTENSIONAHA.117.09321. Epub 2017 Jun 12.</citation>
    <PMID>28607124</PMID>
  </reference>
  <reference>
    <citation>Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003 Jul 31;349(5):427-34.</citation>
    <PMID>12890841</PMID>
  </reference>
  <reference>
    <citation>Mourad JJ, des Guetz G, Debbabi H, Levy BI. Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol. 2008 May;19(5):927-34. Epub 2007 Dec 4.</citation>
    <PMID>18056916</PMID>
  </reference>
  <reference>
    <citation>Lely AT, Salahuddin S, Holwerda KM, Karumanchi SA, Rana S. Circulating lymphangiogenic factors in preeclampsia. Hypertens Pregnancy. 2013;32(1):42-9. doi: 10.3109/10641955.2012.697953. Epub 2012 Sep 7.</citation>
    <PMID>22957504</PMID>
  </reference>
  <reference>
    <citation>Turpin CA, Sakyi SA, Owiredu WK, Ephraim RK, Anto EO. Association between adverse pregnancy outcome and imbalance in angiogenic regulators and oxidative stress biomarkers in gestational hypertension and preeclampsia. BMC Pregnancy Childbirth. 2015 Aug 25;15:189. doi: 10.1186/s12884-015-0624-y.</citation>
    <PMID>26303772</PMID>
  </reference>
  <reference>
    <citation>Wallukat G, Homuth V, Fischer T, Lindschau C, Horstkamp B, Jüpner A, Baur E, Nissen E, Vetter K, Neichel D, Dudenhausen JW, Haller H, Luft FC. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest. 1999 Apr;103(7):945-52.</citation>
    <PMID>10194466</PMID>
  </reference>
  <reference>
    <citation>Signore C, Mills JL, Qian C, Yu K, Lam C, Epstein FH, Karumanchi SA, Levine RJ. Circulating angiogenic factors and placental abruption. Obstet Gynecol. 2006 Aug;108(2):338-44. Erratum in: Obstet Gynecol. 2006 Oct;108(4):1035.</citation>
    <PMID>16880304</PMID>
  </reference>
  <reference>
    <citation>Zhou CC, Irani RA, Zhang Y, Blackwell SC, Mi T, Wen J, Shelat H, Geng YJ, Ramin SM, Kellems RE, Xia Y. Angiotensin receptor agonistic autoantibody-mediated tumor necrosis factor-alpha induction contributes to increased soluble endoglin production in preeclampsia. Circulation. 2010 Jan 26;121(3):436-44. doi: 10.1161/CIRCULATIONAHA.109.902890. Epub 2010 Jan 11.</citation>
    <PMID>20065159</PMID>
  </reference>
  <reference>
    <citation>Artunc-Ulkumen B, Guvenc Y, Goker A, Gozukara C. Relationship of neutrophil gelatinase-associated lipocalin (NGAL) and procalcitonin levels with the presence and severity of the preeclampsia. J Matern Fetal Neonatal Med. 2015 Nov;28(16):1895-900. doi: 10.3109/14767058.2014.972926. Epub 2014 Oct 29.</citation>
    <PMID>25283849</PMID>
  </reference>
  <reference>
    <citation>Yeşil A, Kanawati A, Helvacıoğlu Ç, Kaya C, Özgün ÇG, Cengiz H. Identification of patients at risk for preeclampsia with the use of uterine artery Doppler velocimetry and copeptin. J Matern Fetal Neonatal Med. 2017 Nov;30(22):2763-2768. doi: 10.1080/14767058.2016.1262841. Epub 2016 Dec 7.</citation>
    <PMID>27868455</PMID>
  </reference>
  <reference>
    <citation>Sun IO, Santelli A, Abumoawad A, Eirin A, Ferguson CM, Woollard JR, Lerman A, Textor SC, Puranik AS, Lerman LO. Loss of Renal Peritubular Capillaries in Hypertensive Patients Is Detectable by Urinary Endothelial Microparticle Levels. Hypertension. 2018 Nov;72(5):1180-1188. doi: 10.1161/HYPERTENSIONAHA.118.11766.</citation>
    <PMID>30354805</PMID>
  </reference>
  <reference>
    <citation>Mannaerts D, Faes E, Goovaerts I, Stoop T, Cornette J, Gyselaers W, Spaanderman M, Van Craenenbroeck EM, Jacquemyn Y. Flow-mediated dilation and peripheral arterial tonometry are disturbed in preeclampsia and reflect different aspects of endothelial function. Am J Physiol Regul Integr Comp Physiol. 2017 Nov 1;313(5):R518-R525. doi: 10.1152/ajpregu.00514.2016. Epub 2017 Aug 9.</citation>
    <PMID>28794106</PMID>
  </reference>
  <reference>
    <citation>Palomaki GE, Haddow JE, Haddow HR, Salahuddin S, Geahchan C, Cerdeira AS, Verlohren S, Perschel FH, Horowitz G, Thadhani R, Karumanchi SA, Rana S. Modeling risk for severe adverse outcomes using angiogenic factor measurements in women with suspected preterm preeclampsia. Prenat Diagn. 2015 Apr;35(4):386-93. doi: 10.1002/pd.4554. Epub 2015 Feb 4.</citation>
    <PMID>25641027</PMID>
  </reference>
  <reference>
    <citation>Moore Simas TA, Crawford SL, Solitro MJ, Frost SC, Meyer BA, Maynard SE. Angiogenic factors for the prediction of preeclampsia in high-risk women. Am J Obstet Gynecol. 2007 Sep;197(3):244.e1-8.</citation>
    <PMID>17826405</PMID>
  </reference>
  <reference>
    <citation>Rana S, Powe CE, Salahuddin S, Verlohren S, Perschel FH, Levine RJ, Lim KH, Wenger JB, Thadhani R, Karumanchi SA. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation. 2012 Feb 21;125(7):911-9. doi: 10.1161/CIRCULATIONAHA.111.054361. Epub 2012 Jan 18.</citation>
    <PMID>22261192</PMID>
  </reference>
  <reference>
    <citation>Maynard SE, Crawford SL, Bathgate S, Yan J, Robidoux L, Moore M, Moore Simas TA. Gestational angiogenic biomarker patterns in high risk preeclampsia groups. Am J Obstet Gynecol. 2013 Jul;209(1):53.e1-9. doi: 10.1016/j.ajog.2013.03.017. Epub 2013 Mar 18.</citation>
    <PMID>23517919</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 17, 2020</study_first_submitted>
  <study_first_submitted_qc>August 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2020</study_first_posted>
  <last_update_submitted>August 17, 2020</last_update_submitted>
  <last_update_submitted_qc>August 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pregnancy hypertension</keyword>
  <keyword>Gestational hypertension</keyword>
  <keyword>Pre-eclampsia</keyword>
  <keyword>Microcirculation</keyword>
  <keyword>Endothelial dysfunction</keyword>
  <keyword>Angiogenic biomarkers</keyword>
  <keyword>Soluble Fms-like- tyrosine kinase 1</keyword>
  <keyword>Placental Growth Factor</keyword>
  <keyword>Vascular Endothelial Growth Factor</keyword>
  <keyword>Laser-Doppler flowmetry</keyword>
  <keyword>Acetylcholine iontophoresis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
    <mesh_term>Eclampsia</mesh_term>
    <mesh_term>Hypertension, Pregnancy-Induced</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcholine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

